GlaxoSmithKline plc
Pennsylvania, USA GlaxoSmithKline plc , one of the world's leading research-based pharmaceutical and healthcare companies , is committed to improving the quality of human life by enabling people to ... Cephalon , Inc. Pennsylvania, USA Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and marketing of innovative products in four core therapeutic ... Escalon Medical Corp. Pennsylvania, USA Escalon provides contract manufacturing and design services for the medical device industry, across a variety of technologies and end-use applications. Escalon strives to provide q... Acuity Pharmaceuticals Pennsylvania, USA Acuity is developing treatments for age-related macular degeneration (AMD) and diabetic retinopathy (DR), two of the leading causes of adult blindness in the developed world. Acuit... Locus Pharmaceuticals , Inc. Pennsylvania, USA Locus Pharmaceuticals is a privately held pharmaceutical company focused on developing novel, small molecule therapeutics to address major unmet medical needs. Locus combines power... Pennsylvania, USA PolyMedix develops acute care products for drug resistant bacteria and acute cardiovascular disorders based on biomimetics - novel non-peptide small molecule drugs that mimic the a... The Quigley Corporation Pennsylvania, USA The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufact... AmerisourceBergen Corporation Pennsylvania, USA AmerisourceBergen's focus is to provide the best service in the pharmaceutical supply chain with continuously improving operational efficiencies and expanded offerings and programs... Neuronyx , Inc. Pennsylvania, USA Neuronyx is a pioneer in the use of adult bone marrow-derived somatic cells (hABM-SC) and we believe the first company to test the ability of directly delivered cells to repair dam... Mylan Laboratories Inc. Pennsylvania, USA Mylan is the first company to file a supplemental ANDA for Estradiol Transdermal Systems, 0.0375 mg/day and 0.06 mg/day, and has been awarded a 180-day period of marketing exclusiv... |
All Region
|
